Bosh sahifaMOLN • SWX
add
Molecular Partners AG
Yopilish kursi
3,36 CHF
Kunlik diapazon
3,37 CHF - 3,40 CHF
Yillik diapazon
2,70 CHF - 5,10 CHF
Bozor kapitalizatsiyasi
136,87 mln CHF
Oʻrtacha hajm
48,82 ming
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
SWX
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (CHF) | sen, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | — | — |
Joriy xarajat | 3,60 mln | -18,25% |
Sof foyda | -11,84 mln | 27,85% |
Sof foyda marjasi | — | — |
Har bir ulushga tushum | -0,33 | 32,65% |
EBITDA | -11,40 mln | 18,54% |
Amaldagi soliq stavkasi | — | — |
Balans
Jami aktivlari
Jami passivlari
| (CHF) | sen, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 104,52 mln | -27,22% |
Jami aktivlari | 112,15 mln | -27,27% |
Jami passivlari | 16,62 mln | 7,70% |
Umumiy kapital | 95,53 mln | — |
Tarqatilgan aksiyalar | 37,40 mln | — |
Narxi/balansdagi bahosi | 1,32 | — |
Aktivlardan daromad | -25,23% | — |
Kapitaldan daromad | -29,02% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (CHF) | sen, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -11,84 mln | 27,85% |
Operatsiyalardan naqd pul | -9,93 mln | 25,27% |
Sarmoyadan naqd pul | 10,66 mln | -25,01% |
Moliyadan naqd pul | -304,00 ming | -1,00% |
Naqd pulning sof oʻzgarishi | 384,00 ming | 481,82% |
Boʻsh pul | -5,40 mln | 33,24% |
Haqida
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Tashkil etilgan
2004
Xodimlar soni
153
